Axon Enterprise (NASDAQ:AXON) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Axon Enterprise (NASDAQ:AXON) from a sell rating to a hold rating in a research note issued to investors on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Craig Hallum reiterated a “buy” rating and set a $820.00 price objective on shares of Axon Enterprise in a research report on Wednesday. Northcoast Research raised shares of Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 target price for the company in a research note on Tuesday, January 6th. Citigroup reiterated a “buy” rating on shares of Axon Enterprise in a research note on Wednesday. Morgan Stanley dropped their price objective on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating for the company in a report on Wednesday. Finally, Needham & Company LLC cut their price objective on Axon Enterprise from $870.00 to $600.00 and set a “buy” rating for the company in a research report on Friday, February 20th. Sixteen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $762.93.

Axon Enterprise Price Performance

NASDAQ:AXON opened at $542.40 on Friday. The business’s 50-day simple moving average is $537.92 and its two-hundred day simple moving average is $624.54. Axon Enterprise has a 52 week low of $396.41 and a 52 week high of $885.91. The stock has a market cap of $43.61 billion, a PE ratio of 356.84, a P/E/G ratio of 16.34 and a beta of 1.48. The company has a quick ratio of 2.89, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.55. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The firm had revenue of $796.72 million during the quarter, compared to analysts’ expectations of $755.29 million. During the same quarter last year, the business posted $2.08 earnings per share. The firm’s revenue was up 38.5% on a year-over-year basis. As a group, analysts forecast that Axon Enterprise will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the sale, the president directly owned 249,502 shares of the company’s stock, valued at $137,874,805.20. The trade was a 7.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jeffrey C. Kunins sold 1,797 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the sale, the insider owned 83,485 shares in the company, valued at approximately $45,017,616.55. This trade represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 58,040 shares of company stock valued at $32,251,738 in the last quarter. 4.40% of the stock is currently owned by insiders.

Institutional Trading of Axon Enterprise

Institutional investors have recently bought and sold shares of the stock. NEOS Investment Management LLC raised its holdings in Axon Enterprise by 82.7% in the 3rd quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after purchasing an additional 11,482 shares during the period. Vanguard Group Inc. increased its position in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after buying an additional 376,904 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after buying an additional 5,953 shares in the last quarter. BIT Capital GmbH raised its stake in shares of Axon Enterprise by 75.6% during the 3rd quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock worth $2,537,000 after buying an additional 1,522 shares during the period. Finally, Wealthedge Investment Advisors LLC lifted its position in shares of Axon Enterprise by 180.7% during the 2nd quarter. Wealthedge Investment Advisors LLC now owns 1,204 shares of the biotechnology company’s stock valued at $997,000 after buying an additional 775 shares in the last quarter. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q4 beat and bullish bookings — Axon reported a double beat (EPS and revenue), ~39% revenue growth and a material increase in future contracted bookings with raised multi‑year sales targets, which triggered the stock rally. Read More.
• Positive Sentiment: AI narrative driving subscription demand — Coverage highlights that Axon’s AI features (body‑camera analytics, Draft One report drafting, evidence management) are accelerating software adoption and upsells, supporting revenue visibility beyond hardware. Read More.
• Neutral Sentiment: Analysts recalibrating models — Several firms trimmed price targets after the print (Piper Sandler, others); many maintained buy/overweight stances, so these moves reflect model updates and volatility rather than a wholesale negative verdict. Read More.
• Neutral Sentiment: Short‑interest data flagged as anomalous — Recent short‑interest reports show zero/NaN figures (likely a reporting anomaly); nothing actionable from that data point for now.
• Negative Sentiment: Some analysts flag downside risk — Morgan Stanley and UBS issued more cautious outlooks/pessimistic scenarios that could cap upside if execution or margins slip. Read More. | Read More.
• Negative Sentiment: Profitability and margin recovery remain a watch item — Commentators note fast revenue growth but slower profit improvement and the need for FCF conversion; sustained margin progress is required to justify high multiples. Read More.
• Negative Sentiment: Insider sale disclosed — CEO Patrick Smith sold 10,000 shares (~$5.0M) on Feb. 25; small relative to his holdings but notable to traders monitoring insider activity. Read More.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.